TechCrunch ; Why are VCs launching SPACs? Amish Jani of FirstMark shares his fir

Why are VCs launching SPACs? Amish Jani of FirstMark shares his firm’s rationale
It’s happening slowly but surely. With every passing week, more venture firms are beginning to announce SPACs. The veritable blitz of SPACs formed by investor Chamath Palihapitiya notwithstanding, we’ve now seen a SPAC (or plans for a SPAC) revealed by Ribbit Capital, Lux Capital, the travel-focused venture firm Thayer Ventures, Tusk Ventures’s founder Bradley Tusk, the SoftBank Vision Fund, and FirstMark Capital, among others. Indeed, while many firms say they’re still in the information-gathering phase of what could become a sweeping new trend, others are diving in headfirst.
To better understand what’s happening out there, we talked on Friday with Amish Jani, the cofounder of FirstMark Capital in New York and the president of a new $360 million tech-focused blank-check company organized by Jani and his partner, Rick Heitzmann. We wanted to know why a venture firm that has historically focused on early-stage, privately held companies would be interested in public market investing, how Jani and Heitzmann will manage the regulatory requirements, and whether the firm may encounter conflicts of interest, among other things.
If you’re curious about starting a SPAC or investing in one or just want to understand how they relate to venture firms, we hope it’s useful reading. Our chat has been edited for length and clarity.

TC: Why SPACs right now? Is it fair to say it’s a shortcut to a hot public market, in a time when no one quite knows when the markets could shift?
AJ: There are a couple of different threads that are coming together. I think the first one is the the possibility that [SPACs] works and really well. [Our portfolio company] DraftKings [reverse-merged into a SPAC] and did a [private investment in public equity deal]; it was a fairly complicated transaction and they used this to go public and the stock has done incredibly well.
In parallel, [privately held companies] over the last five or six years could raise large sums of capital, and that was pushing out the the timeline [to going public] fairly substantially. [Now there are] tens of billions of dollars in value sitting in the private markets and [at the same time] an opportunity to go public and build trust with public shareholders and leverage the early tailwinds of growth.
TC: DraftKings was valued at $3 billion when it came out and it’s now valued at $17 billion, so it has performed really, really well. What makes an ideal target for a SPAC versus a traditional IPO? Does having a consumer-facing business help get public market investors excited? That seems the case.
AJ: It comes down to the nature and the growth characteristics and the sustainability of the business. The early businesses that are going out, as you point out, tend to be consumer based, but I think there’s as good an opportunity for enterprise software companies to use the SPAC to go public.
SPAC [targets] are very similar to what you would want in a traditional IPO: companies with large markets, extremely strong management teams, operating profiles that are attractive, and long term margin profiles that are sustainable, and to be able to articulate [all of that] and have the governance and infrastructure to operate in a public context. You need to be able to do that across any of these products that you use to get public.
TC: DraftKings CEO Jason Robins is an advisor on your SPAC. Why jump into sponsoring one of these yourselves?
AJ: When he was initially approached, we were, like most folks, pretty skeptical. But as the conversations evolved, and we began to understand the amount of customization and flexibility [a SPAC can offer], it felt very familiar. [Also] the whole point of backing entrepreneurs is they do things differently. They’re disruptive, they like to try different formats, and really innovate, and when we saw through the SPAC and the [actual merger] this complex transaction where you’re going through an M&A and raising capital alongside that and it’s all happening between an entrepreneur and a trusted partner, and they’ve coming to terms before even having to talk about all of these things very publicly, that felt like a really interesting avenue to create innovation.
For us, we’re lead partners and directors in the companies that we’re involved with; we start at the early stages at the seed [round] and Series A and work with these entrepreneurs for over a decade, and if we can step in with this product and innovate on behalf of our entrepreneurs and entrepreneurs in tech more broadly, we think there’s a really great opportunity to push forward the process for how companies get public.
TC: You raised $360 million for your SPAC. Who are its investors? Are the same institutional investors who invest in your venture fund? Are these hedge funds that are looking to deploy money and also potentially get their money out faster?
AJ: I think a bit of a misconception is this idea that most investors in the public markets want to be hot money or fast money. You know, there are a lot of investors that are interested in being part of a company’s journey and who’ve been frustrated because they’ve been frozen out of being able to access these companies as they’ve stayed private longe. So our investors are some are our [limited partners], but the vast majority are long-only funds, alternative investment managers, and people who are really excited about technology asa long term disrupter and want to be aligned with this next generation of iconic companies.
TC: How big a transaction are you looking to make with what you’ve raised?
AJ: The targets that we’re looking for are going to look very similar to the kind of dilution that a great company would take going public — think of that 15%, plus or minus, around that envelope. As you do the math on that, you’re looking at a company that’s somewhere around $3 billion in value. We’re going to have conversations with a lot of different folks who we know well, but that’s that’s generally what we’re looking for.
TC: Can you talk about your “promote,” meaning how the economics are going to work for your team?
AJ: Ours [terms] are very standard to the typical SPAC. We have 20% of the original founders shares. And that’s a very traditional structure as you think about venture funds and private equity firms and hedge funds: 20% is is very typical.
TC: It sounds like your SPAC might be one in a series.
AJ: Well, one step at a time. The job is to do this really well and focus on this task. And then we’ll see based on the reaction that we’re getting as we talk to targets and how the world evolves whether we do a second or third one.
TC: How involved would you be with the management of the merged company and if the answer is very, does that limit the number of companies that might want to reverse-merge into your SPAC?
AJ: The management teams of the companies that we will target will continue to run their businesses. When we talk about active involvement, it’s very much consistent with how we operate as a venture firm, [meaning] we’re a strong partner to the entrepreneur, we are a sounding board, we help them accelerate their businesses, we give them access to resources, and we leverage the FirstMark platform. When you go through the [merger], you look at what the existing board looks like, you look at our board and what we bring to bear there, and then you decide what makes the most sense going forward. And I think that’s going to be the approach that we take.
TC: Chamath Palihapitiya tweeted yesterday about a day when there could be so many VCs with SPACs that two board members from the same portfolio company might approach it to take it public. Does that sound like a plausible scenario and if so, what would you do?
AJ: That’s a really provocative and interesting idea and you could take that further and say, maybe they’ll form a syndicate of SPACs. The way I think about it is that competition is a good thing. It’s a great thing for entrepreneurship, it’s a good thing overall.
The market is actually really broad. I think there’s something like 700-plus private unicorns that are out there. And while there are a lot of headlines around the SPAC, if you think about technology-focused people with deep tech backgrounds, that pool gets very, very limited, very quickly. So we’re pretty excited about the ability to go have these conversations.

WSJ : Disney Elevates Streaming Business in Major Reorganization

Disney Elevates Streaming Business in Major Reorganization
Company forms new content and distribution arms as pandemic hammers entertainment industry

Walt Disney Co. DIS -0.01% announced a major reorganization meant to give priority to its streaming-video services and ensure they get a steady flow of the company’s best content, in a shift echoing similar moves by other entertainment giants.

Under the new structure, Disney is creating content groups for movies, general entertainment and sports. It is also forming a distribution arm to determine the best platform for any given content, whether that is a streaming service, a TV network or movie theaters.

The new alignment pushes Disney’s streaming platforms, including Disney+ and Hulu, even closer to the center of the company. The various programming arms, including movie and television studios, will be aiming to feed those streaming services, not just legacy outlets.

Disney Chief Executive Bob Chapek said the moves are a recognition of how consumers are changing their consumption habits, favoring streaming platforms over movie theaters and traditional broadcast and cable channels.

“There is a seismic shift happening in the marketplace, and you can either lead or follow and we chose to lead,” Mr. Chapek said of the company’s push into streaming, adding that the focus is now on “what platform is best to meet those consumer needs.”

The Covid-19 pandemic continues to slam the entertainment industry, and Disney has been particularly hard hit. Its Disneyland theme park in Southern California is still closed, and attendance at parks that have been reopened hasn’t returned to normal. Many movie theaters around the nation remain closed or at limited capacity.

Streaming services have been among the bright spots for Disney and other media companies during the coronavirus crisis, as consumers who are working from home and skipping vacations watch more content. Disney+, which said in August it had over 60 million subscribers world-wide, has been a big beneficiary of the pandemic’s streaming surge.

Disney has faced external pressure to pivot more aggressively toward its streaming business, especially given the struggles of its legacy businesses such as cable networks. Activist investor Daniel Loeb, whose Third Point Capital is one of Disney’s biggest stockholders, sent a letter recently to Mr. Chapek calling for Disney to devote more resources to its streaming operations.

Disney is the latest entertainment giant to reorient its business by separating decisions over which shows and movies should be produced from decisions over which platforms are best suited to carry them. Comcast Corp.’s NBCUniversal has restructured much of its content business with this goal in mind, looking to elevate its Peacock streaming service, while AT&T Inc.’s WarnerMedia is centralizing its creative operations in hopes of bolstering its HBO Max service.

The media and entertainment distribution unit Disney has created will be overseen by Kareem Daniel, who most recently was president of consumer products, games and publishing. That unit will handle the distribution of Disney content as well as advertising and technology.

A Disney veteran, Mr. Daniel has also had stints in Disney’s strategy and business development unit and its motion-picture distribution business. Mr. Chapek said having distribution under Mr. Daniel will allow the company to “make our distribution decisions in a less preconceived notion.”

The content side will be headed by the same executives currently in charge of movies, TV and sports. Disney Studios Co-Chairmen Alan Horn and Alan Bergman will oversee the new movie arm. Peter Rice, who oversees TV production for Disney, will become chairman of general entertainment content, while ESPN head Jimmy Pitaro will head the sports unit.

Disney Chairman and former CEO Robert Iger will also continue to have an active role in content creation, the company said.

Mr. Daniel and the heads of the content units will all report to Mr. Chapek.

The new content structure could end confusion in Hollywood about who is calling the shots regarding television content for Disney+. There had been some tension between Mr. Rice’s unit and Disney+’s own programming team, people familiar with the matter said.

Mr. Chapek played down any friction between the two, saying, “The same people that have been collaborating in the past will be collaborating in the future.”

Rebecca Campbell, who was brought in to oversee Disney+ just last May, will continue in that role but now reports to Mr. Daniel. She will also head international operations and report to Mr. Chapek.

The bulk of Disney’s revenue still comes from its legacy businesses, including cable programming networks such as ESPN, Disney Channel and Freeform, which have suffered declines in subscribers and ratings due to cable cord-cutting.

Ratings for the NBA Finals between the Los Angeles Lakers and Miami Heat were far below past years, amid competition with other live sports such as the National Football League. The fact the basketball playoffs were played at all during the pandemic—in an Orlando “bubble”—was viewed by many in the sports world as a success that averted a disaster for the league and its TV partners. The NFL, meantime, has had to postpone games as it struggles to contain a Covid-19 outbreak.

The theatrical film business was already facing challenges before the coronavirus shut down theaters across the country. The virus has led some movie studios to shorten the time between when a film arrives in theaters and when it appears on other platforms such as on-demand and streaming services—accelerating what industry observers saw as an inevitable shift.

Disney released its big summer movie “Mulan” on Disney+ at a cost of $30. It is also moving its Pixar movie “Soul” to the service but at no extra charge.

Mr. Chapek said that the company still believes in the theatrical business but that Disney needs the “freedom to take a strong pipeline of content and place it where it makes the most sense.”

Nikkei : Apple ramps up production ahead of 5G iPhone debut

Apple ramps up production ahead of 5G iPhone debut
Long-awaited lineup to be unveiled in California on Oct. 13

TAIPEI -- Apple and its key suppliers are ramping up production and working through holidays to make sure the long-awaited 5G iPhone range will hit shelves soon after it is unveiled on Oct. 13.

The two most important iPhone assemblers, Foxconn and Pegatron, have been running at full production speed during China's two most important holidays -- the Mid-Autumn Festival and the Golden Week holiday that follows its National Day -- Nikkei Asia has learned.

Initial production of the highly anticipated 5G iPhone began around mid-September, in line with Nikkei Asia's previous report, with more substantial production output starting in early October. Both Apple and its suppliers have been working hard for months to shorten the production delay caused by the coronavirus pandemic.

The production volume for the new 5G iPhone range could end up between 73 million and 74 million units for this year, Nikkei Asia reported, falling short of Apple's original orders for up 80 million units' worth of components due to production and development delays caused by the coronavirus outbreak. The production shortfall will likely be made up early next year, if sales are as strong Apple expects. Production of all the latest iPhones and the flagship 5G lineup remains in China, despite the tech industry's huge migration out of the country, Nikkei reported.

Foxconn said it does "not comment on any aspect of our operations or our work for any customer" as a matter of policy. "However, we can say that all holiday and overtime work arrangements carried out by employees in our facilities in China are entirely voluntary and they fully comply with all relevant laws and regulations."

Pegatron declined to comment on specific clients or products.

Apple last week sent out an invitation for an online press event on Oct. 13 to announce the release of the 5G iPhones, weeks after it hosted a virtual event to launch new iPads and Apple Watch and about one month later than it usually unveils its flagship iPhones.

The Cupertino-based tech giant is set to introduce four models of 5G iPhones with three screen sizes: 5.4-inches, 6.1-inches and 6.7-inches. All four of the phones will sport the most advanced organic light-emitting diode displays, which is mostly supplied by Samsung Display and LG Display of South Korea.

Two of the 5G iPhones -- the 6.1-inch and 6.7-inch models -- will come with high-end triple cameras, which will likely feature an artificial intelligence-powered object detection feature that could better enable augmented reality applications. The other two models will sport dual cameras like last year's popular iPhone 11.

The full 5G iPhone range will be powered by Apple's in-house designed A14 mobile processors, which are produced by Taiwan Semiconductor Manufacturing Co. using the Taiwanese company's latest 5-nanometer chip production technology -- currently the industry's most advanced.

The new iPhones will be the first smartphones in the world to use such advanced chips, following Apple's announcement in September that its new iPad Air will also boast the A14 chips. Apple will also not include a charger or wired earphones with its new iPhones, both to keep costs down and because many iPhone users already have these accessories.

Apple's launch of its flagship iPhones comes as its embattled rival Huawei Technologies -- which briefly overtook Samsung Electronics' as the world's leading smartphone maker by shipments in the June quarter -- announced it will launch its flagship Mate 40 smartphone on Oct. 22.

Huawei is battling an ongoing U.S. clampdown that restricts all suppliers, American or not, from using American technology to serve the Chinese tech giant unless they receive a specific license. This restriction has affected everyone from TSMC, Micron and Samsung to Sony, Qualcomm and Largan Precision, a high-end camera lens provider.

The Mate 40 models will be equipped with Huawei's in-house designed Kirin mobile processor, which, like Apple's A14 chip, is produced by TSMC using 5-nanometer technology. Because Huawei cannot receive support from unlicensed chip suppliers, however, the company's chip supply may run out. Huawei's Mate series usually competes head-to-head with Apple's new iPhones in the final quarter of the year.

Growing geopolitical tensions could also impact Apple's 5G iPhone sales in China if the Trump administration forces the company to remove popular Chinese apps like WeChat or TikTok from its app store. Meanwhile Beijing in September rolled out a set of rules for its "Unreliable Entity List," a list of foreign companies accused of treating Chinese companies unfairly. The Global Times, the mouthpiece of the Chinese Communist Party, previously hinted that Apple, Qualcomm and Cisco Systems could be among the potential targets of Beijing's retaliation.

While market watchers foresee more uncertainty for the smartphone market due to the pandemic and geopolitical tensions, they are hopeful of a recovery in 2021.

Luke Lin, an analyst with Digitimes, expects Samsung, Apple, Oppo, Vivo and Xiaomi to see healthy growth in smartphone shipment next year, while Huawei will see a significant decline due to the U.S. crackdown. Total iPhone sales will surpass 220 million units in 2021, from around 195 million units this year, and Apple will reclaim the No. 2 position in the global smartphone market, according to Lin's forecast.

FT : IEA warns of slowest decade of energy demand growth since 1930s

IEA warns of slowest decade of energy demand growth since 1930s
Global body says delayed recovery will leave ‘deep scars’ into the 2030s

A prolonged battle with the pandemic and a weaker global economy will usher in the slowest decade of worldwide energy demand growth since the 1930s, the International Energy Agency said on Tuesday.

“The Covid-19 pandemic has caused more disruption to the energy sector than any other event in recent history, leaving impacts that will be felt for years to come,” the Paris-based body said in its long-term outlook

In its “stated policies” or base-case scenario, which assumes coronavirus is controlled and the global economy returns to pre-pandemic levels in 2021, consumption rebounds to its pre-crisis level in early 2023.

Yet government officials and business executives increasingly warn of the persistent effects of the virus. The IEA acknowledged that “hopes for a rapid halt to the global spread of the coronavirus and its economic fallout have dissipated”.

In the IEA’s “delayed recovery” scenario, energy demand does not return to pre-pandemic levels until at least 2025, after which the impact of the virus continues to be felt for years to come.

“Much of the damage sustained during a decade of subdued recovery from the pandemic leaves deep scars in the 2030s,” the IEA said in the report, which is published annually. “The longer-term energy impacts of a delayed recovery from Covid-19 are still visible in 2040.”

Before the crisis, energy demand — across oil, gas, coal and renewables — was projected to grow by 12 per cent between 2019 and 2030. Growth over this period weakens to 9 per cent in the base-case scenario, and 4 per cent in the delayed recovery model.

The latter scenario implies further outbreaks of coronavirus and government measures to curb the spread. It also assumes that longer-term economic growth is “impaired” and that there are lasting changes in consumer behaviour. 

“A prolonged recovery means a permanent downward revision to energy production and consumption for most regions,” the IEA added.

Coal takes the largest hit. Oil and natural gas eventually return to growth, but the recovery in oil demand takes until 2027, after which global consumption levels out at just under 100m b/d — roughly in line with 2019 consumption levels.

“We think the era of global oil demand growth will come to an end in the next 10 years,” Fatih Birol, head of the IEA, told the Financial Times. The energy body had previously said oil demand would level out in the mid-2030s.

Demand stemming from the transport sector would bear the brunt of the initial shock from coronavirus, said the IEA, adding that long-haul travel — particularly aviation — faced longer-term distress. Power generation and industrial energy use would also suffer “lasting damage” in a prolonged recovery.

Opec producer nations expect oil demand to keep growing for the next two decades, in contrast to a growing proportion of the energy sector that believes a peak in consumption is nearing. 

Oil major BP has modelled three scenarios that all suggest oil demand will fall over the next 30 years. Two of them imply consumption will never fully recover to pre-pandemic levels. 

In the IEA’s delayed recovery scenario, alongside lower than anticipated demand, prices are expected to remain volatile. This, the energy body said, would increase the economic and social pressures on big producer countries that relied on hydrocarbon revenues.

Despite weaker energy demand that is expected to lead to a drop in carbon dioxide emissions, this was still “far from sufficient” to meet the Paris climate goals of limiting temperature rises to well below 2C, the IEA added.

>>> What to look at today - 13th of October 2020

 U.S. futures slipped and Asian stocks were mixed Tuesday as investors weighed a potential setback on progress toward a coronavirus vaccine against an overnight surge in technology shares. The dollar and Treasuries advanced.
S&P 500 contracts retreated after a report that Johnson & Johnson’s Covid-19 vaccine study has been paused due to an unexplained illness in a participant. Stocks remained higher in Australia, fluctuated in Japan and dipped in South Korea and China. Earlier, the S&P 500 closed higher for a fourth day and technology leaders including Amazon.com Inc., Apple Inc. and Twitter Inc. helped the Nasdaq 100 to its biggest advance since April.
The Australian dollar slid amid reports that China has suspended purchases of Australian coal. Hong Kong scrapped its trading session as a tropical storm neared.
US After Hours ETH +12% gains on Q1 outlook update while VYGR -12% drops on regulatory update for VY-HTT01 program

Nikkei +0.13% Hang Seng Closed CSI -0.02% Shanghai -0.28% Shenzen +0.24%

Eur$ 1.1798 CNH 6.7479 CNY 6.7509 JPY 105.42 GBP 1.3050 VHF 0.9095 RUB 77.12 WTI$ 39.48 +0.13%

S&P -0.40% Nasdaq -0.34% EuroStoxx -0.09% FTSE +0.25% Dax +0.05% SMI +0.09%

Macro :
- IEA Sees Oil Demand Suffering Long-Lasting Blow From Coronavirus
- U.K. Public in Highest Risk Covid Areas Told to Limit Travel
- China’s Exports Gain, Imports Surge in September Amid Reopenings
- Europe Braces for Surge in Covid Patients to Hit Hospitals Soon

Keep an eye on :
- AIR FP : Airbus Says French Union Deal Averts Compulsory Job Cuts
- BBY LN : Balfour Beatty Seeks New Chairman as Aiken Plans to Leave: Sky
- BSLN SW : Basilea Reports Successful Completion of Phase 1B Pt of FIDES-02
- BO DC : B&O CEO Says Myth That Company Too Small to Stay Independent: JP
- DIC GY : DIC Asset Won’t Pursue Issuance of Corporate Bond
- EVT GY : Evotec to Sell 11.5m Shares to Mubadala And Novo for EU250m
- EVT GY : Abu Dhabi Wealth Fund Mubadala to Invest $235 Million in Evotec
- FAGR BB : Fagron Third Quarter Organic Revenue +8.2%
- FSKRS FH : Fiskars Reinstates FY Ebita Growth Guidance After ‘Positive’ 3Q
- GSK LN : Surface Oncology Gains on Report of Glaxo Takeover Interest
- GXI GY : Gerresheimer Confirms FY Revenue View After 3Q Revenue Miss (1)
- IVA FP : Inventiva: FDA Grants Breakthrough Designation to Lanifibranor
- MC FP : EC Review of Tiffany/LVMH Not Showing Any Issues: Dealreporter
- MOR GY : MorphoSys to Offer EU325m Convertibles With 0.625%-1.125% Coupon
- ROG SW : Roche to Launch Laboratory SARS-Cov-2 Antigen Test
- SBRE LN : Sabre Insurance Says Performance is Consistent With Expectations
- SALM NO : Salmar: Icelandic Salmon Contemplated Placement, Merkur Listing
- SAN FP : Sanofi France Head Sees Covid Vaccine Results by December
- SAN FP : Sanofi: Dupixent Significantly Cut Asthma Attacks in Children
- TIF US : EC Review of Tiffany/LVMH Not Showing Any Issues: Dealreporter
- URW NA : Unibail-Rodamco-Westfield to Sell Office Building for EU620m
- UCG IM : UniCredit May List Foreign Asset Holding Co. Separately: Sole
- VRLA FP : Verallia Names Nathalie Delbreuve as CFO, Effective Nov. 2
- VIV FP : Fortress Said to Bid $1.1 Billion for Italy’s Serie A TV Rights
- WDI GY : KPMG Was Auditor to Wirecard’s Mauritian Counterparty: FT

>>> Europe : Brokers Upgrades & Downgrades -13th of October 2020

>>> Up
* Adecco Raised to Overweight at JPMorgan; PT 58 Swiss francs
* H&M Raised to Add at AlphaValue
* Huhtamaki Raised to Accumulate at OP Corporate Bank
* Kingspan Raised to Buy at SocGen; PT 90 euros
* Naked Wines PLC Raised to Buy at Peel Hunt; PT 535 pence
* Pets at Home PT Raised to 460 pence from 355 pence at Citi
* Rockwool Raised to Hold at SocGen; PT 2,700 kroner
* Schindler Raised to Sector Perform at RBC; PT 245 Swiss francs
* Subsea 7 Raised to Buy at Jefferies; PT 90 kroner
* TalkTalk Raised to Hold at Berenberg; PT 97 pence
* TechnipFMC Raised to Hold at Jefferies; PT $7
* Worldline PT Raised to 110 euros from 92 euros at Jefferies

>>> Down
* Airbus Cut to Underweight from Neutral by JPMorgan Cazenove
* Autogrill Cut to Sell at Citi; PT 2.50 euros
* Danone Cut to Underperform at Bernstein; PT 53 euros
* Petrofac Cut to Neutral at Exane; PT 135 pence
* Scandic Cut to Underweight at Morgan Stanley; PT 21 kronor
* Simcorp Cut to Sell at SEB Equities; PT 775 kroner

>>> Initiation
* Beiersdorf Rated New Outperform at Bernstein; PT 120 euros
* BMW Cut to Hold at Commerzbank; PT 68 euros
* Greatland Gold Rated New Hold at Berenberg; PT 22 pence
* Henkel Rated New Underperform at Bernstein
* Lindt & Spruengli Rated New Outperform at Bernstein
* L'Oreal Rated New Outperform at Bernstein; PT 340 euros
* Nestle Rated New Outperform at Bernstein; PT 120 Swiss francs
* SBM Offshore Rated New Outperform at Exane; PT 20 euros
* S4 Capital Rated New Buy at Pivotal; PT 500 pence
* Unilever Rated New Underperform at Bernstein
* Orkla Rated New Market Perform at Bernstein; PT 90 kroner

>>> Call
* Autogrill ‘Stuck in a Rut,’ With Earnings Risk to Downside: Citi
* BMW Positive Upside Limited, Margins Near Peak, Commerzbank Says
* Naked Wines Upgraded on U.K. Strength, U.S. Potential: Peel Hunt
* Scandic Downgraded, Morgan Stanley Sees Liquidity Shortfall Risk
* Schindler Upgraded at RBC as Valuation Back in Line With History
* Subsea 7 Upgraded at Jefferies on Wind, O&G Offshore Advantage

(DJ)MorphoSys AG Launches an Offering of approx. EUR 325 Mil Convertible Bonds

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announces to launch an offering of unsubordinated, unsecured convertible bonds due 2025 in an aggregate principal amount of approximately EUR 325 million. The bonds will be convertible into up to approximately 2.65 million new and/or existing no-par value ordinary bearer shares of MorphoSys. The pre-emptive rights (Bezugsrechte) of existing shareholders of the Company to subscribe for the convertible bonds will be excluded.

The convertible bonds with a denomination of EUR 100,000 each will be issued at 100% of their principal amount. Unless previously converted, redeemed or repurchased and cancelled, the convertible bonds will be redeemed at their principal amount on October 16, 2025. The convertible bonds will be offered with a coupon between 0.625% and 1.125% per annum, payable semi-annually in arrear. The conversion premium will be set between 35.0% and 40.0% above the reference share price, being the volume-weighted average price (VWAP) of the shares on XETRA between launch and pricing.

The Company may redeem all, but not some only, of the convertible bonds outstanding at their principal amount plus accrued interest with effect on or after November 6, 2023 if the price of the Company's share is equal to or exceeds 130% of the prevailing conversion price on each day within a certain period, or if less than 20% of the aggregate principal amount of the convertible bonds originally issued are outstanding.

The convertible bonds will be offered by way of an accelerated bookbuilding process to institutional investors outside the United States of America and any other jurisdiction in which offers or sales of the convertible bonds would be prohibited by applicable law.

The final terms of the convertible bonds are expected to be determined and announced later today through a separate press release. Settlement of the offering is expected to take place on or around October 16, 2020. The Company intends to arrange for the convertible bonds to be included to trading on the Open Market Segment (Freiverkehr) of the Frankfurt Stock Exchange shortly thereafter.

Use of Proceeds

The proceeds from the issue of the convertible bonds will be used for general corporate purposes, including proprietary development, inlicensing and/or M&A transactions.

Lock-up

The Company has agreed to a lock-up of 90 calendar days following the settlement of the offering, subject to customary exemptions.

WSJ : Johnson & Johnson Pauses Covid-19 Vaccine Trials Due to Sick Subject

Johnson & Johnson Pauses Covid-19 Vaccine Trials Due to Sick Subject
Company says an independent committee is reviewing the subject’s illness

Johnson & Johnson said it has paused further dosing in all clinical trials of its experimental Covid-19 vaccine because a study volunteer had an unexplained illness.

The pause announced Monday affects all trials of J&J’s vaccine, including a large Phase 3 trial that began in September and aimed to enroll as many as 60,000 people in the U.S. and several other countries.

An independent data-safety monitoring board is reviewing the study subject’s illness, the company said. The company didn’t immediately disclose more information about the illness, and said it needed to respect the subject’s privacy.

This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern. Last month, AstraZeneca PLC paused clinical trials of an experimental Covid-19 vaccine after a participant in a U.K. study had an unexplained illness. The U.K. study resumed, but a large U.S. study is still on hold.

J&J, of New Brunswick, N.J., said illnesses and other side effects are an expected part of any clinical study, and it has prespecified guidelines to monitor for the events.

The guidelines “ensure our studies may be paused if an unexpected serious adverse event that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study,” the company said.

The pause was earlier reported by Stat News.

J&J’s vaccine is one of the most advanced Covid-19 shots in development, among just a handful that had entered the last stage of testing in the U.S., after entrants from AstraZeneca, Moderna Inc. and Pfizer Inc.

Company officials had estimated the Phase 3 trial could begin providing results either by the end of the year or in early 2021, and the shots could be authorized for use in early 2021.

Drugmakers including J&J have developed their Covid-19 shots remarkably quickly. Vaccines typically take years to bring to market, and many often don’t make it because they fail to work safely during testing.

Side effects often turn up during clinical trials. Sometimes, they don’t turn out to have a link to the vaccine. But if the independent experts monitoring the safety of the trial find a link, the safety issue can derail the experimental shot.

The safety board needs to assess whether the subject’s illness was related to the vaccine or not, a person familiar with the matter said.

J&J’s plan for its Phase 3 study sets out criteria for pausing the testing, including if a subject has a serious adverse event that is determined to be related to the vaccine, or if someone has a severe allergic reaction, known as anaphylaxis, or hives, that can’t be attributed to something other than the vaccine.

The company’s shot uses a weakened version of a common cold virus, which is engineered to deliver genetic instructions teaching the body’s cells to make a protein resembling one found on the surface of the coronavirus. This, in turn, induces the body’s immune system to build up defenses against the coronavirus if a person subsequently is exposed to it.

The common cold virus used in the vaccine is modified so that it can’t replicate and cause disease.

J&J co-developed the vaccine with Beth Israel Deaconess Medical Center in Boston.

AstraZeneca’s trials were paused after a woman in a U.K. study of their vaccine had an unexplained illness, which a U.S. health official described as a spinal-cord problem. This followed an earlier pause in July to the U.K. study after another subject had symptoms that researchers later concluded was multiple sclerosis and unrelated to the vaccine.

U.K. authorities allowed the U.K. trial to resume in September after concluding it was safe to do so. Trials have resumed in several other countries including Japan and Brazil, but the U.S. trial remains paused while AstraZeneca works with the Food and Drug Administration in reviewing the information needed to make a decision regarding resumption of the trial.

AstraZeneca’s vaccine also uses a weakened version of a common cold virus, but one from chimpanzees instead of humans.

WSJ : Blackstone-Backed Finance of America Is Set for IPO

Blackstone-Backed Finance of America Is Set for IPO
Lender to go public with a $1.9 billion valuation by merging with blank-check firm Replay Acquisition

Consumer-lending platform and Blackstone Group Inc. BX 0.46% portfolio company Finance of America Equity Capital LLC is set to go public with a valuation of $1.9 billion through a blank-check merger, this year’s hottest way to list shares, according to people familiar with the matter.

Finance of America is set to merge with the special-purpose acquisition company, or SPAC, Replay Acquisition Corp. RPLA -0.58% , the people said. In conjunction with the merger, institutional investors will also make a private investment of $250 million in the company. In all, the deal will leave the consumer lender’s founder and funds managed by Blackstone with a 70% ownership stake.

SPACs are all the rage in 2020, quickly having become a favored way for companies to go public in a year when initial public offerings are hotter than ever. Their popularity is a sign that there is more demand for newly listed companies than there are companies going public. So far this year, companies have raised more than $109 billion going public in the U.S., surpassing every other full year on record, according to Dealogic, whose data go back to 1995. SPACs have accounted for almost half of that total.

The sole purpose of SPACs, which are also known as blank-check companies, is to raise money to acquire a private target and take it public. Founders of these shell companies pitch their names or expertise in certain industries; once they have raised a certain amount of money they have a specific amount of time, typically two years, to identify a target. Announced deals are subject to shareholder approval. Finance of America’s services include traditional mortgages, reverse mortgages, commercial-real-estate loans and fixed-income investing. It has grown via a series of acquisitions and over the past roughly five years as a portfolio company of Blackstone’s Tactical Opportunities business, which can invest across any asset class, industry, sector, security type or geography.

The move is the latest in a recent spate of financial dealmaking. This summer, Quicken Loans parent Rocket Cos. went public through a traditional IPO. Last month, wholesale mortgage originator United Wholesale Mortgage said it intended to go public via a SPAC, and Caliber Home Loans Inc. is also prepping an IPO. Morgan Stanley recently struck a deal to buy fund manager Eaton Vance Corp., and activist investor Nelson Peltz invested in Invesco Ltd. and Janus Henderson Group PLC, planning to agitate for a deal.

The new listings come as the mortgage market has held up surprisingly well in the face of the coronavirus pandemic, with the Mortgage Bankers Association expecting mortgage originations to hit recent highs in 2020. Record-low interest rates are also driving refinancings, with the Mortgage Bankers Association expecting mortgage originations to hit recent highs in 2020. Record-low interest rates are also driving refinancings.

Finance of America had been considering a traditional IPO but then earlier this summer began speaking with the founders of Replay Acquisition Corp., one of the people said. Though the money raised in the deal goes to current owners, the person said becoming a publicly traded company allow the consumer-lending platform to raise additional capital more easily going forward.